EDIT

Editas Medicine
$2.68
+$0.08 (+3.08%)Jul 27, 2026
2.9FairMoatMint rating

MoatMint rates Editas Medicine (EDIT) 2.9 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 3.4 out of 10.

Key metrics

The numbers that frame EDIT today
Market cap
$262.39M
P/E (TTM)
-2.4
EV / FCF
-1.5
Gross margin
100%
EV / Sales
5.4
ROIC
-167%
Div yield
0%
Debt / equity
16.3
52wk Low
$1.66
52wk High
$4.54

EDIT stock rating

How EDIT scores on quality, value, growth, momentum and financial health
2.9out of 10
Fair overallHealthy business, expensive priceTop 71% of ~5,000 US stocks
QualityFair3.4/10
GrowthGreat9.2/10
MomentumNeutral4.1/10
ValuePoor0.8/10
Financial HealthFair2.4/10

Growth

Revenue and earnings trend for EDIT
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about EDIT
Is Editas Medicine a good buy?
No. Editas Medicine has weak quality and weak momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup. We think Editas Medicine is selling at a very high price.
What is the market capitalization of EDIT?
Editas Medicine's market capitalization is $262.39M.
What is the P/E ratio for EDIT stock?
Editas Medicine's current P/E ratio is -2.4.
What is the 52-week high for EDIT stock?
The 52-week high for Editas Medicine is $4.54. The current close of $2.68 is 40.9% below that high.
What is the 52-week low for EDIT stock?
The 52-week low for Editas Medicine is $1.66. The current close of $2.68 is 61.4% above that low.
Does EDIT stock pay dividends?
Editas Medicine does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for EDIT?
Editas Medicine's Debt / Equity ratio is 16.33.